CVS shares rise 3.28% as report on retail pharmacy separation circulates
Key Facts
CVS shares rose 3.28% to $91.41 at the close of trading on November 3, after reports circulated about a possible separation of the company’s retail pharmacy business into a standalone listed entity. Bloomberg cited a Financial Times report saying the proposal under discussion would keep Aetna, the insurance arm, and Caremark, the pharmacy benefits manager, within the parent company. Reuters reported that discussions remain at an early stage and that no final decision has been made on a separation. The structure described therefore remains a possibility under discussion, not an announced plan for implementation. The proposal in circulation centers on separating the pharmacy stores from the insurance and pharmacy benefits management businesses.
CVS brings together a broad range of activities across pharmacies, healthcare, insurance and pharmacy benefits management. The company said its network included about 9,000 retail pharmacy locations and more than 1,000 primary care and walk-in clinics as of June 30, 2026. It added that its pharmacy benefits manager had about 87 million members, while its insurance products and related services served about 37 million people. These figures illustrate the scale of the activities that the proposal in circulation would separate, from retail outlets to drug coverage management and insurance. But the reports did not specify how assets, customers or contracts would be allocated between the parent and a potential entity.
Caremark’s position between pharmacies and insurance puts operational links at the heart of any potential reorganization. According to Bloomberg’s account of the Financial Times report, Caremark would remain with Aetna under the parent company if CVS proceeds with the proposal under discussion. The Associated Press reported that pharmacy benefits managers handle pharmacy claims on behalf of insurers and negotiate with drugmakers over prices and covered medications. It added that CVS and two other large companies manage most prescriptions in the United States. That means the reported separation targets the retail business, while the insurance and benefits management businesses would remain together under the proposal as reported.
The discussions come as legislative interest in pharmacy benefits managers grows at the state level. The Associated Press said lawmakers in at least 26 states introduced more than 120 bills related to these companies during 2026. In Tennessee, a law bars benefits managers from operating retail pharmacies starting July 1, 2028. The agency reported that CVS filed a federal lawsuit to avoid closing its 136 pharmacies in the state. This regulatory backdrop provides context for the overlap between benefits management and store operations, but does not establish that it prompted the review described in the reports.
The company’s background reflects an earlier expansion that brought insurance, pharmacy and healthcare under one group. CVS completed its acquisition of Aetna on November 28, 2018, saying at the time that combining the companies’ capabilities would build a local care model, simplify the system and lower costs for patients. Reuters valued the deal at about $78 billion and described a potential separation as a move that could unwind part of a conglomerate built through a series of acquisitions. In the second-quarter 2026 results, total revenue was $106.1 billion, up 7.3% year over year. Adjusted operating income in the health services segment also rose 10.0%, while revenue in the pharmacy and consumer wellness segment was $33.816 billion, compared with $33.581 billion in the corresponding period of 2025.
The company raised its 2026 adjusted earnings-per-share guidance to a range of $7.90–$8.10, from $7.30–$7.50, and lifted its operating cash flow forecast to at least $11.5 billion from $9.5 billion. These estimates provide financial context for the discussion, but do not specify expected savings or costs from a potential separation. CVS said it would hold a call to discuss its third-quarter results on November 4, 2026, at 8:00 a.m. Eastern Time. The call is the nearest formally announced opportunity to communicate with investors after the reports circulated. The announcement did not confirm that management would address the review on the call or provide a timeline for any separation.